XML 11 R19.htm IDEA: XBRL DOCUMENT v3.20.1
NOTE 13 – RELATED PARTIES
 3 Months Ended
Mar. 31, 2020
Related Party Transactions [Abstract]  
NOTE 13 – RELATED PARTIES

NOTE 13 – RELATED PARTIES

 

In July 2015, J. Martin Carroll, a director of our company, was appointed to the board of directors of Catalent, Inc. From time to time, we have entered into agreements with Catalent, Inc. and its affiliates, or Catalent, in the normal course of business. Agreements with Catalent have been reviewed by independent directors of our company, or a committee consisting of independent directors of our company, since July 2015. During the three months ended March 31, 2020 and 2019, we were billed by Catalent approximately $1,303,000 and $1,397,000, respectively, for manufacturing activities related to our clinical trials, scale-up, registration batches, stability and validation testing. As of March 31, 2020 and December 31, 2019, there were amounts due to Catalent of approximately $755,000 and $35,000, respectively. In addition, we have minimum purchase requirements in place with Catalent as disclosed in Note 15, Commitments and Contingencies.